0.00Open0.00Pre Close0 Volume0 Open Interest20.00Strike Price0.00Turnover0.00%IV--PremiumJul 19, 2024Expiry Date--Intrinsic Value100Multiplier16DDays to Expiry--Extrinsic Value100Contract Size--Options Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Everbridge Stock Discussion
UiPath is expected to report a 24.4% increase in revenue to $383.826 million from $308.55 million a year ago, UiPath's guidance on 30 Jan 2023, for the period ended 31 Jan was for revenue between $381.00 million and $386.00 million.
Looking at UiPath's peers in the automation software...
Gapping up
$Zillow-A(ZG.US)$ +5.5% (Zillow Group was upgraded by Piper Sandler to overweight from neutral. Analyst Thomas Champion also hiked his price target to $62 per share, suggesting 33% upside from Monday's close.)
$JPMorgan(JPM.US)$ +1.2% (JPMorgan Chase was upgraded from Jefferies to buy from hold. The firm also labeled JPMorgan Chase as“best-in-class.")
$3M(MMM.US)$ +2% (Shares rose n...
In reaction to earnings/guidance:
• $The Trade Desk(TTD.US)$+17%, $Workiva(WK.US)$ +15.3%, $Arlo Technologies(ARLO.US)$ +12%, $Array Technologies(ARRY.US)$ +10.3%, $Everbridge(EVBG.US)$ +9.7%, $Catalyst Pharmaceuticals(CPRX.US)$ +9.4%, $Halozyme Therapeutics(HALO.US)$ +8.7%, $Velo3D(VLD.US)$ +7.6%, $CyberArk(CYBR.US)$ + 6.2%, $Haemonetics(HAE.US)$ +5.8%, $Jackson Financial(JXN.US)$ +5.7% (also increases dividend), $Axon Enterprise(AXON.US)$ +4.8%, ...
No comment yet